{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:42:19Z","timestamp":1789846939582,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,12,5]],"date-time":"2007-12-05T00:00:00Z","timestamp":1196812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s10585-007-9127-1","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T16:21:42Z","timestamp":1196958102000},"page":"119-129","source":"Crossref","is-referenced-by-count":179,"title":["Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis"],"prefix":"10.1007","volume":"25","author":[{"given":"Jude R.","family":"Canon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Roudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Morony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Stolina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Kostenuik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Dougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,12,5]]},"reference":[{"key":"9127_CR1","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588\u20131594","journal-title":"Cancer"},{"key":"9127_CR2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/8756-3282(94)90703-X","volume":"15","author":"T Taube","year":"1994","unstructured":"Taube T, Elomaa I, Blomqvist C et\u00a0al (1994) Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 15:161\u2013166","journal-title":"Bone"},{"key":"9127_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"9127_CR4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1084\/jem.188.5.997","volume":"188","author":"K Fuller","year":"1998","unstructured":"Fuller K, Wong B, Fox S et\u00a0al (1998) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188:997\u20131001","journal-title":"J Exp Med"},{"key":"9127_CR5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","volume":"397","author":"YY Kong","year":"1999","unstructured":"Kong YY, Yoshida H, Sarosi I et\u00a0al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315\u2013323","journal-title":"Nature"},{"key":"9127_CR6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","volume":"157","author":"DL Lacey","year":"2000","unstructured":"Lacey DL, Tan HL, Lu J et\u00a0al (2000) Osteoprotegerin ligand modulates murine osteoclast survival in\u00a0vitro and in\u00a0vivo. Am J Pathol 157:435\u2013448","journal-title":"Am J Pathol"},{"key":"9127_CR7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL et\u00a0al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165\u2013176","journal-title":"Cell"},{"key":"9127_CR8","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"N Bucay","year":"1998","unstructured":"Bucay N, Sarosi I, Dunstan CR et\u00a0al (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260\u20131268","journal-title":"Genes Dev"},{"key":"9127_CR9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR et\u00a0al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309\u2013319","journal-title":"Cell"},{"key":"9127_CR10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342","journal-title":"Nature"},{"key":"9127_CR11","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655\u20131664","journal-title":"N Engl J Med"},{"key":"9127_CR12","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF et\u00a0al (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102:1064\u20131069","journal-title":"Blood"},{"key":"9127_CR13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/02841860600635870","volume":"46","author":"G Mountzios","year":"2006","unstructured":"Mountzios G, Dimopolous M-A, Bamias A et\u00a0al (2006) Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor\/kB ligand (RANKL)\/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 46:221\u2013229","journal-title":"Acta Oncol"},{"key":"9127_CR14","first-page":"4432","volume":"61","author":"S Morony","year":"2001","unstructured":"Morony S, Capparelli C, Sarosi I et\u00a0al (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432\u20134436","journal-title":"Cancer Res"},{"key":"9127_CR15","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1359\/JBMR.041010","volume":"20","author":"R Miller","year":"2005","unstructured":"Miller R, Jones J, Tometsko M et\u00a0al (2005) Antitumor efficacy of the RANK ligand inhibitor OPG-Fc in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models. J Bone Miner Res 20:S117","journal-title":"J Bone Miner Res"},{"key":"9127_CR16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bone.2006.09.016","volume":"40","author":"Y Zheng","year":"2007","unstructured":"Zheng Y, Zhou H, Brennan K et\u00a0al (2007) Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40:471\u2013478","journal-title":"Bone"},{"key":"9127_CR17","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1359\/jbmr.2000.15.2.209","volume":"15","author":"S Morony","year":"2000","unstructured":"Morony S, Sarosi I, Doerr N et\u00a0al (2000) OPG prevents bone destruction and decreases skeletal tumor burden in an experimental model of tumor metastasis to bone. J Bone Miner Res 15:S209","journal-title":"J Bone Miner Res"},{"key":"9127_CR18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10555-006-9021-3","volume":"25","author":"WC Dougall","year":"2006","unstructured":"Dougall WC, Chaisson M (2006) The RANK\/RANKL\/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 25:541\u2013549","journal-title":"Cancer Metastasis Rev"},{"key":"9127_CR19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584\u2013593","journal-title":"Nat Rev Cancer"},{"key":"9127_CR20","first-page":"3551","volume":"55","author":"A Sasaki","year":"1995","unstructured":"Sasaki A, Boyce BF, Story B et\u00a0al (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551\u20133557","journal-title":"Cancer Res"},{"key":"9127_CR21","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","volume":"72","author":"T Dull","year":"1998","unstructured":"Dull T, Zufferey R, Kelly M et\u00a0al (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463\u20138471","journal-title":"J Virol"},{"key":"9127_CR22","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1359\/jbmr.1999.14.9.1478","volume":"14","author":"S Morony","year":"1999","unstructured":"Morony S, Capparelli C, Lee R et\u00a0al (1999) A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1,25(OH)2D3. J Bone Miner Res 14:1478\u20131485","journal-title":"J Bone Miner Res"},{"key":"9127_CR23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2220\/biomedres.26.159","volume":"26","author":"T Shimamura","year":"2005","unstructured":"Shimamura T, Amizuka N, Li M et\u00a0al (2005) Histological observations on the microenvironment of osteolytic bone metastasis by breast carcinoma cell line. Biomed Res 26:159\u2013172","journal-title":"Biomed Res"},{"key":"9127_CR24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.1199","volume":"198","author":"S Kitazawa","year":"2002","unstructured":"Kitazawa S, Kitazawa R (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198:228\u2013236","journal-title":"J Pathol"},{"key":"9127_CR25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/jsre.2001.6204","volume":"100","author":"AT Mancino","year":"2001","unstructured":"Mancino AT, Klimberg VS, Yamamoto M et\u00a0al (2001) Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100:18\u201324","journal-title":"J Surg Res"},{"key":"9127_CR26","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","volume":"140","author":"RJ Thomas","year":"1999","unstructured":"Thomas RJ, Guise TA, Yin JJ et\u00a0al (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451\u20134458","journal-title":"Endocrinology"},{"key":"9127_CR27","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1158\/0008-5472.CAN-04-4188","volume":"65","author":"G Pluijm van der","year":"2005","unstructured":"van der Pluijm G, Que I, Sijmons B et\u00a0al (2005) Interference with the microenvironmental support impairs the de novo formation of bone metastases in\u00a0vivo. Cancer Res 65:7682\u20137690","journal-title":"Cancer Res"},{"key":"9127_CR28","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1210\/en.2004-1583","volume":"146","author":"S Morony","year":"2005","unstructured":"Morony S, Warmington K, Adamu S et\u00a0al (2005) The RANKL inhibitor osteoprotegerin (OPG) causes greater suppression of bone resorption and hypercalcemia compared to bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 146:3235\u20133243","journal-title":"Endocrinology"},{"key":"9127_CR29","doi-asserted-by":"crossref","first-page":"11001","DOI":"10.1158\/0008-5472.CAN-05-2630","volume":"65","author":"MS Bendre","year":"2005","unstructured":"Bendre MS, Margulies AG, Walser B et\u00a0al (2005) Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65:11001\u201311009","journal-title":"Cancer Res"},{"key":"9127_CR30","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature04524","volume":"440","author":"DH Jones","year":"2006","unstructured":"Jones DH, Nakashima T, Sanchez OH et\u00a0al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692\u2013696","journal-title":"Nature"},{"key":"9127_CR31","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1128\/MCB.01298-06","volume":"27","author":"E Gonzalez-Suarez","year":"2007","unstructured":"Gonzalez-Suarez E, Branstetter D, Armstrong A et\u00a0al (2007) RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol Cell Biol 27:1442\u20131454","journal-title":"Mol Cell Biol"},{"issue":"Supp 1","key":"9127_CR32","first-page":"6124","volume":"100","author":"M Roudier","year":"2006","unstructured":"Roudier M, Chaisson M, Branstetter D et\u00a0al (2006) RANK is expressed in human breast tumors and is functional on breast cancer cells. Breast Cancer 100(Supp 1):6124","journal-title":"Breast Cancer"},{"key":"9127_CR33","first-page":"287","volume":"63","author":"K Vanderkerken","year":"2003","unstructured":"Vanderkerken K, De Leenheer E, Shipman C et\u00a0al (2003) Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 63:287\u2013289","journal-title":"Cancer Res"},{"key":"9127_CR34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P et\u00a0al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59\u201369","journal-title":"J Natl Cancer Inst"},{"key":"9127_CR35","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","volume":"23","author":"RE Coleman","year":"2005","unstructured":"Coleman RE, Major P, Lipton A et\u00a0al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925\u20134935","journal-title":"J Clin Oncol"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-007-9127-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-007-9127-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-007-9127-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T03:14:33Z","timestamp":1708398873000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-007-9127-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,5]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["9127"],"URL":"https:\/\/doi.org\/10.1007\/s10585-007-9127-1","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,5]]}}}